TP53 and breast cancer: The structural nature of TP53 mutations thus seem to be relevant in term of clinical outcome, an issue which has also been reported by Seagle et al. (2015) who focused on the impact of various structurally-grouped missense mutations in the TCGA ovarian and breast cancer cohorts [20].